Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

Primary Insomnia Linked To A Neurochemical Abnormality
A research abstract presented on June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, is the first demonstration of a specific neurochemical abnormality in adults with primary insomnia (PI), providing greater insight to the limited understanding of the condition"s pathology.
buy viagra
Washington Post Opinion Piece Examines O'Reilly's Role In Tiller Murder
Fox News host Bill O"Reilly is "being incredibly disingenuous when he claims that he bears no responsibility for others" actions in the killing of Dr. George Tiller on Sunday," Mary Alice Carr, vice president of communications for NARAL Pro-Choice New York, writes in a Washington Post opinion piece. "When you tell an audience of millions over and over again that someone is an executioner, you cannot feign surprise when someone executes that person," she continues, adding that "O"Reilly knew that people wanted Tiller dead, and he knew full well that many of those people were avid viewers of his show. Still, he fanned the flames."Carr writes that she has pledged to no longer appear on O"Reilly"s show because she realized that her appearance "would only legitimize his speech and that no good would come of my efforts." She adds that when a producer called her to come on the show following Tiller"s murder, she responded that, among other things, the community of abortion-rights supporters "hold[s] O"Reilly responsible for helping to create a climate in which hate was allowed to fester."Carr notes that following Tiller"s death, "O"Reilly had the opportunity to apologize for his words" and "say that this tragic outcome was something about which he felt sorry," but "[h]e didn"t." She adds, "When restraint and perspective were called for, he fanned the flames higher." Carr concludes that she will not appear on O"Reilly"s show because "if the murder of a man in a house of worship wasn"t enough to make Bill O"Reilly repent, what hope d[o] I have?" (Carr, Washington Post, 6/4).
News of the day
British System Highlights Cost-Effectiveness Concerns As Part Of U.S. Overhaul Effort
While Congress recently approved funds to study the cost-effectiveness of certain treatments, some are concerned that such research could lead to rationing of health care or that treatments deemed less effective will not be adequately covered, the AP/Washington Post reports. Those concerned often cite Great Britain"s National Institute for Health and Clinical Excellence, which determines which medical treatments will be covered based on cost-effectiveness. One of the criteria used by NICE to determine a treatment"s cost-effectiveness is how much each additional year of life will cost the government, which the agency has capped at about $47,000 per year of life in most cases (Cheng, AP/Washington Post, 5/26).
Health Insurance

MMWR Report On Gonorrhea And Chlamydia Incidence Among MSM Spurs AHF To Call For FDA Approval Of Newer Testing Technologies

On the heels of the publication today of a landmark, five city US study of gonorrhea and Chlamydia infections and related testing protocols among populations of at-risk men-who-have-sex-with-men (MSM), the AIDS Healthcare Foundation (AHF)-a clinical participant in the research trial component in Los Angeles- called on the Food and Drug Administration (FDA) to fast track approval of newer and alternative testing technologies highlighted in the study for use in the diagnosis of gonorrhea and Chlamydia infections among high-risk populations. The study, "Clinic-based Testing for Rectal and Pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis Infections by Community-based Organizations-Five Cities, United States, 2007" published in the respected Centers for Disease Control"s (CDC) Morbidity and Mortality Weekly Report (MMWR, July 9, 2009), found that one testing protocol, nucleic acid amplification (NAA), is, "ò€¦generally more sensitive and favored by most experts," particularly for extragenital testing (for rectal and pharyngeal specimens); however, "NAA tests have not been cleared by the Food and Drug Administration (FDA) for the diagnosisò€¦and may not be marketed for that purpose." "AIDS Healthcare Foundation was one of six community-based health organizations serving men-who-have-sex-with-men that participated in this study under Dr. Jeffrey Klausner"s stewardship. The results of this study are pretty straightforward, and we believe suggest simple, but prudent changes in the approval of such testing protocols by the FDA," said Homayoon Khanlou, MD, Chief of Medicine, US, for AIDS Healthcare Foundation. "Today, testing for both gonorrhea and Chlamydia can also be done by culture and by nucleic acid amplification. This study has shown that there are better, quicker returns and rates with NAA testing versus cultures, with NAA test results often available within 48 hours, while results of cultures are generally not available within that same timeframe." The study also noted that, "Manufacturers of NAA tests should pursue FDA clearance of those tests for the diagnosis of rectal and pharyngeal gonorrhea and chlamydia by gathering and submitting to the FDA sufficient data on test performance for those indications. In the interim, CDC and the Association of Public Health Laboratories can further help support increases in NAA testing by providing technical assistance and specimens to laboratories for use in verification studies," and that, "ò€¦community-based organizations increasingly can be effective partners in the STD prevention efforts to control rectal and pharyngeal gonorrhea and Chlamydia, and possibly reduce HIV transmission in MSM." "We know that gonorrhea or Chlamydia infections can be significant co-factors in the transmission of HIV," added AHF"s Khanlou. "Presently, the CDC recommends a minimum of annual routine testing for gonorrhea and Chlamydia for at-risk MSMs. Looking at this study, we now strongly urge the FDA to fast track approval of NAA testing for gonorrhea and Chlamydia from rectal and pharyngeal specimens to streamline and improve testing for both of those diseases which, in turn, may also contribute to a reduction in the transmission of HIV infections among at-risk individuals who could also have either of those other STDs." AIDS Healthcare Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009